Treace Medical price target raised to $9 from $7 at Truist

Truist raised the firm’s price target on Treace Medical to $9 from $7 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results in the MedTech sector. Across the market cap, there continues to be crowding in the strongest growth stories with a widening performance and valuation gap between “haves” and “have nots”, but while this could create some profit-taking, dips in these names will get bought if fundamentals are moving in the right direction, the analyst tells investors in a research note. For Teleflex, Truist notes that while it expects the company to deliver at least an in-line revenue result in Q2, the stock is not expected to “sustainably re-rate” even on a beat and raise as it will take several quarters of execution before investors can regain confidence in the company’s growth algorithm.